Bulletin from the annual general meeting in EQL Pharma AB on 17 August 2021
Today, on 17 August 2021, the annual general meeting was held in EQL Pharma AB. In light of the ongoing Covid-19 pandemic and in order to reduce the risk of infection spreading, the annual general meeting was held only by advance voting (postal vote) in accordance with temporary legislation. A summary of the adopted resolutions follows below. All resolutions were adopted with the required majority of votes.
Resolution on adoption of accounts and allocation of the company’s result
The annual general meeting resolved to adopt the income statement and balance sheet as well as the consolidated income statement and the consolidated balance sheet. The annual general meeting also resolved to distribute the company’s result in accordance with the proposal from the board of directors in the annual report meaning that no dividends are paid for the financial year 2020/2021 and that the available funds are carried forward.
Discharge from liability for the members of the board of directors and the CEO
The annual general meeting resolved to discharge the members of the board of directors and the CEO from liability for the financial year 2020/2021.
Election and remuneration of the board of directors and auditors
The annual general meeting resolved in accordance with the proposal from the Nomination Committee to re-elect Anders Månsson, Christer Fåhraeus, Linda Neckmar and Rajiv I Modi as members of the board of directors and to elect Per Ollermark and Per Svangren as new members of the board of directors for the period until the end of the next annual general meeting. Anders Månsson was re-elected as Chairman of the board of directors. Lars Holmqvist and Maria Bech had declined re-election as board members.
The annual general meeting further resolved that board remuneration shall be paid with SEK 250,000 to the Chairman of the board of directors and with SEK 100,000 to each of the other board members who are not permanent employees in the company.
The annual general meeting finally resolved in accordance with the proposal from the Nomination Committee to re-elect Crowe Osborne AB as auditor and that remuneration to the auditor shall be paid in accordance with approved invoice. Crowe Osborne AB has informed that the authorized public accountant Olov Strömberg will continue to be the auditor in charge.
Resolution on instruction for the Nomination Committee
The annual general meeting resolved in accordance with the proposal from the Nomination Committee that a Nomination Committee shall be appointed before coming election and remuneration. The Nomination Committee shall be comprised of three members, representing the three largest registered owners in terms of votes as of 31 December 2021. Furthermore, an instruction for the Nomination Committee was adopted.
Resolution on implementation of a long-term incentive program
The annual general meeting resolved in accordance with the proposal from the board of directors to implement a long-term incentive program for two senior executives and one key person in the company based on issue of warrants.
The incentive program shall comprise a maximum of 142,000 warrants. Each warrant entitles the right to subscribe for one new share in the company for a subscription price per share corresponding to 200 per cent of the volume weighted average price according to Spotlight Stock Market’s official price list for shares in the company during ten trading days after the annual general meeting on 17 August 2021. The warrants shall be issued to the fair market value of the warrants at the time of subscription, which shall be determined by an independent valuation institute in accordance with the Black & Scholes valuation formula. Subscription of shares by virtue of the warrants may be effected from and including 1 September 2025 to and including 30 September 2025.
In case all warrants issued in connection with the incentive program are exercised for subscription of new shares, a total of 142,000 new shares will be issued, which corresponds to a dilution of approximately 0.49 per cent of the company’s share capital and votes after full dilution, calculated on the number of shares that will be added upon full utilization of all warrants issued under the incentive program.
For further information, please contact:
Christer Fåhraeus
CEO, EQL Pharma AB (publ)
Phone: +46 (0) 705 – 60 90 00
E-mail: christer.fahraeus@eqlpharma.com
Website: www.eqlpharma.com
EQL Pharma AB (publ) in short
EQL Pharma AB specializes in developing and selling generics, i.e. medicines that are medically equivalent to originator medicines. The company currently has 17 niche generics (i.e. generics with little or no competition apart from the originator drug) approved in the Nordic markets. In addition to these, there exist a significant pipeline of additional niche generics for launch in 2021 and beyond. The business is currently entirely focused on prescription drugs. EQL Pharma AB conducts its operations in Lund, employs 10 people and is listed on the Spotlight Stock Market. EQL Pharma AB conducts extensive development work in collaboration with leading contract manufacturers and major pharmaceutical companies in the EU, India and China, among others.